Incomplete Inhalation of Laninamivir Octanoate in Children with Influenza

نویسندگان

  • Yoshiki Katsumi
  • Osamu Otabe
  • Satoshi Sakaue
  • Yusuke Tsuma
  • Mihoko Yamaguchi
  • Fumihiro Matsui
  • Masaya Suematsu
چکیده

Background: Laninamivir octanoate (LO), an inhaled neuraminidase inhibitor, has been used against influenza in Japan. However, children who cannot inhale well might not receive the full dose. We examined the relation between the residual amounts of LO in the device after its use and the time to fever resolution in children with influenza. Methods: The subjects of the study were 161 children (4-15 years) who had been diagnosed as having influenza from 2011-2014 and who had demonstrated an ability to properly use an inhalation training device. After its use, the LO device was returned to the authors and the residual amount of LO was measured. After flu symptoms had resolved, the patients’ parents reported the time to fever resolution in a questionnaire. Results: The percentage of the residual LO was not significantly correlated with the time to fever resolution or with patient age. The percentage of residual LO tended to be higher and the time to fever resolution tended to be longer in 4-6 year-olds than in older children. In the 4-6 year group, seven patients were inhaling steroids. These patients tended to inhale more of the LO dose and tended to have a shorter time to fever resolution than the other patients. Conclusions: Physicians need to be aware that some 4-6 year-old influenza patients will not be able to inhale the full dose of LO. Influenza patients, even young ones, who are also inhaling steroids for other conditions are better able to inhale LO. *Corresponding author: Yoshiki Katsumi, Departments of Pediatrics, Nantan General Hospital, Yagi-Ueno 25, Yagi-cho, Nantan-city, Kyoto 629-0197, Japan, Tel: +81-771-42-2510; Fax: +81-771-42-2096; E-mail: [email protected] Received November 17, 2014; Accepted December 12, 2014; Published December 14, 2014 Citation: Katsumi Y, Otabe O, Sakaue S, Tsuma Y, Yamaguchi M, et al. (2015) Incomplete Inhalation of Laninamivir Octanoate in Children with Influenza. Pediat Therapeut 5: 225. doi:10.4172/2161-0665.1000225 Copyright: © 2014 Katsumi Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

منابع مشابه

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

We conducted a double-blind, randomized controlled trial to compare a long-acting neuraminidase inhibitor, laninamivir octanoate, with oseltamivir. Eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36-h duration. Patients were randomized to 1 of 3 treatment groups: a group given 40 mg laninamivir (40-mg group), a group given 20 mg lanina...

متن کامل

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial

Laninamivir octanoate, a long-acting neuraminidase inhibitor, is an effective treatment for influenza. However, its effectiveness for the prevention of influenza has not yet been demonstrated. We conducted a double-blind, multicenter, randomized, placebo-controlled trial to determine whether laninamivir octanoate was superior to a placebo for post-exposure prophylaxis of influenza in household ...

متن کامل

Effect of a single inhalation of laninamivir octanoate in children with influenza.

OBJECTIVE The purpose of this study was to compare the efficiency and safety of a new neuraminidase inhibitor, laninamivir octanoate (LO), with zanamivir (ZN) in pediatric patients with influenza. METHODS One hundred twelve pediatric patients ≤ 15 years, diagnosed with a rapid diagnostic test as having influenza from January to May 2011, were randomly assigned to the LO group or the ZN group,...

متن کامل

Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

Background A dry powder inhaled formulation is used for the anti-influenza drug laninamivir octanoate hydrate (laninamivir). Although two successive inhalations (puffs) are recommended to minimize residual amounts of active ingredients, previous reports suggest that pediatric patients with low peak inspiratory flow are unable to inhale the active ingredient adequately. In the present study, we ...

متن کامل

Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

A single inhaled dose of laninamivir octanoate (LO), a long-acting neuraminidase inhibitor, exhibits efficacy in treating both adult and pediatric patients with influenza virus infection. The intrapulmonary pharmacokinetics (PK) of LO and laninamivir, a pharmacologically active metabolite, were investigated by a single-center, open-label study of healthy adult volunteers. Subgroups of five subj...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

متن کامل
عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2014